04.01.15
CenterVue Inc. has received U.S. Food and Drug Administration 510(k) clearance for its Eidon true-color confocal scanner. The company claims Eidon is the first, fully-automated retinal imaging system available in the global eye care market that combines the advantages of confocal scanning with true-color imaging capabilities.
Eidon's white-light, confocal imaging technology facilitates diagnosis and management of retinal disease. The combination of confocal imaging and white light illumination provides greater contrast and improved image quality over a traditional fundus camera. Furthermore, the retinal appearance with Eidon’s white-light source mirrors that as seen during white-light, direct observational techniques. Eidon’s optics allow imaging of the central retina as well as the periphery, over a viewing angle of up to 110 degrees. Eidon's multiple imaging modalities –- true-color, red-free, and infrared --- provide information concerning different layers of the retina.
“Eidon's combination of white illumination with confocal imaging provides better image quality. The confocal aperture provides sharp visualization of detail. Confocal white light technology allows us to obtain real color images through a small pupil. The infrared light images detect what the human eye is not able to see. What once was a dream, is now a reality,” said professor Giovanni Staurenghi, Eye Clinic director at the University of Milano and Sacco Hospital in Italy.
Eidon streamlines image acquisition and ensures minimum operator involvement by automatically aligning the patient's pupil, focusing on the retina, and capturing images using a soft light source, the company said. Eidon can be used automatically or manually, with or without pupil dilation. It is operated via a dedicated software application as a standalone unit by means of a high-resolution multi-touch tablet.
“We are excited to launch Eidon as a breakthrough innovation in retinal imaging,” said William Burnham, vice president of Sales and Marketing at CenterVue.
CenterVue develops diagnostic systems for the early detection of sight-threatening pathologies, such as diabetic retinopathy and macular degeneration. The company is headquartered n Padova, Italy, and operates a U.S. subsidiary in Fremont, Calif.
Eidon's white-light, confocal imaging technology facilitates diagnosis and management of retinal disease. The combination of confocal imaging and white light illumination provides greater contrast and improved image quality over a traditional fundus camera. Furthermore, the retinal appearance with Eidon’s white-light source mirrors that as seen during white-light, direct observational techniques. Eidon’s optics allow imaging of the central retina as well as the periphery, over a viewing angle of up to 110 degrees. Eidon's multiple imaging modalities –- true-color, red-free, and infrared --- provide information concerning different layers of the retina.
“Eidon's combination of white illumination with confocal imaging provides better image quality. The confocal aperture provides sharp visualization of detail. Confocal white light technology allows us to obtain real color images through a small pupil. The infrared light images detect what the human eye is not able to see. What once was a dream, is now a reality,” said professor Giovanni Staurenghi, Eye Clinic director at the University of Milano and Sacco Hospital in Italy.
Eidon streamlines image acquisition and ensures minimum operator involvement by automatically aligning the patient's pupil, focusing on the retina, and capturing images using a soft light source, the company said. Eidon can be used automatically or manually, with or without pupil dilation. It is operated via a dedicated software application as a standalone unit by means of a high-resolution multi-touch tablet.
“We are excited to launch Eidon as a breakthrough innovation in retinal imaging,” said William Burnham, vice president of Sales and Marketing at CenterVue.
CenterVue develops diagnostic systems for the early detection of sight-threatening pathologies, such as diabetic retinopathy and macular degeneration. The company is headquartered n Padova, Italy, and operates a U.S. subsidiary in Fremont, Calif.